NCC Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2025 ,inter alia, to consider and approve Un-Audited Financial Results for the Second Quarter and Half Year ended September 30, 2025

pdf

NCC Ltd.

27 Oct 2025, 10:32AM

212.39

0.85%

NCC share up 3% on securing orders worth 6,829 cr from Central Coalfields

Business Standard

NCC share price moved northwards after securing an order worth approximately 6,828.94 crore from Central Coalfields.

NCC Ltd. is trading above its 50 day SMA of 211.0

NCC Ltd.

25 Oct 2025

212.39

0.85%

NCC bags 6,828 crore order from Coal India arm to extract, transport coal

Business Standard

NCC Ltd on Saturday said it has bagged a Rs 6,828.94 crore order from Coal India arm Central Coalfields to extract and transport coal and overburden from one of the mining projects in Jharkhand. In a regulatory filing, the company said it has received a letter of acceptance dated October 24 from Central Coalfields Ltd (CCL) regarding this. The extraction and transportation of overburden and coal will have to be done from the Amrapali open-cast project of CCL in the Chandragupt area of Jharkhand, NCC said in the regulatory filing. NCC will hire Heavy Earth Moving Machinery (HEMM) for the removal of 413.59 M CuM of OB (overburden), extraction of 233.325 MT coal and transportation to Shivpur siding and surface stock yard under different lead slabs and wagon loading of 139.995 MT of coal at Shivpur siding at Amrapali OCP, Chandragupt Area, the filing said. NCC Ltd is a construction company involved in diversified activities, including buildings, transportation, water and environment, .

NCC Ltd. has an average target of 279.80 from 5 brokers.

NCC bags 6,829 cr order from Coal India arm

Business Line | 25 Oct 2025

NCC Ltd.

25 Oct 2025

212.39

0.85%

Company Update

NCC Ltd - 500294 - Announcement under Regulation 30 (LODR)-Award of Order Receipt of Order

BSE India

Disclosure regarding receipt of Major Order

pdf

NCC Ltd.

16 Oct 2025

212.39

0.85%

Company Update

NCC Ltd - 500294 - Announcement under Regulation 30 (LODR)-Credit Rating

BSE India

Disclosure regarding ESG Rating by CFC Finlease Private Limited

pdf

NCC Ltd.

10 Oct 2025

212.39

0.85%

Company Update

NCC Ltd - 500294 - Re-Lodgement Of Transfer Requests Of Physical Shares

BSE India

Re-lodgement of Transfer requests of Physical Shares

pdf

NCC Ltd.

06 Oct 2025

212.39

0.85%

Company Update

NCC Ltd - 500294 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Certificate in terms of Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018

pdf

NCC Ltd.

26 Sep 2025

212.39

0.85%

SAST

NCC Ltd - 500294 - Closure of Trading Window

BSE India

Intimation regarding Closure of Trading Window

pdf

NCC Ltd.

17 Sep 2025

212.39

0.85%

India among top global contributors in reporting drug adverse events: DGCI

Business Standard

India ranks among the top contributors globally in reporting adverse events, Drugs Controller General of India (DCGI) Dr Rajeev Raghuvanshi said on Wednesday. He made the remarks at an event as he highlighted the growing role of pharmacovigilance in safeguarding patient health. The Indian Pharmacopoeia Commission (IPC), functioning as the National Coordination Centre for the Pharmacovigilance Programme of India (NCC-PvPI), inaugurated the 5th National Pharmacovigilance Week (NPW) at the Bharat Mandapam Convention Centre. The National Pharmacovigilance Week is being observed from September 17 to September 23 under the theme 'Your Safety, Just a Click Away: Report to PvPI'. The week-long campaign aims to sensitise healthcare professionals, regulators, researchers and the public to actively report adverse drug reactions (ADRs) through simplified digital platforms. "Initiation of National Pharmacovigilance Week in the journey of pharmacovigilance in the country has changed the course

NCC Ltd. is trading above its 50 day SMA of 211.0

Is NCC Ltd. worth buying?

1864 Votes:

Buy 81.49%

Sell 9.71%

Hold 8.8%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf